MMP2

Matrix Metalloproteinase 2 (MMP2), also known as gelatinase A, is a zinc-dependent endopeptidase that plays a critical role in the degradation and remodeling of the extracellular matrix (ECM). It is primarily responsible for the degradation of type IV and V collagen, fibronectin, laminin, and elastin, which are essential components of the ECM. MMP2 is secreted as an inactive pro-enzyme (proMMP2) and activated through proteolytic cleavage, with its activity being precisely regulated by tissue inhibitors of metalloproteinases (TIMPs). Dysregulation of MMP2 has been linked to a variety of pathological conditions, including cardiovascular diseases, diabetic complications, kidney diseases, and cancer.
MMP2's involvement in disease pathogenesis is complex and multifaceted. It contributes to vascular remodeling, atherosclerosis, and aneurysms in cardiovascular diseases, and mediates excessive ECM degradation leading to tissue scarring in fibrotic diseases. In diabetes, elevated MMP2 activity exacerbates complications such as nephropathy, retinopathy, and cardiovascular disease. In cancer, MMP2 facilitates tumor invasion and metastasis by degrading ECM components and promoting angiogenesis. Targeting MMP2 for therapeutic purposes presents challenges due to its dual functions in tissue remodeling and repair, raising concerns about unplanned consequences such as impaired tissue healing or excessive tissue damage. However, clinical trials targeting MMP2 modulation highlight the potential of gelatinase inhibitors, including those targeting MMP2, to reduce tumor progression in fibrosarcoma, breast, and lung cancers.